University of Tübingen, Department of Otolaryngology, Tübingen Hearing Research Centre, Molecular Physiology of Hearing, Elfriede-Aulhorn-Str. 5, 72076 Tübingen, Germany.
Trends Pharmacol Sci. 2011 Jun;32(6):366-75. doi: 10.1016/j.tips.2011.02.012. Epub 2011 Mar 28.
Within the family of voltage-gated calcium channels (VGCCs), L-type channels (L-VGCCs) represent a well-established therapeutic target for calcium channel blockers, which are widely used to treat hypertension and myocardial ischemia. L-VGCCs outside the cardiovascular system also control key physiological processes such as neuronal plasticity, sensory cell function (e.g. in the inner ear and retina) and endocrine function (e.g. in pancreatic beta cells and adrenal chromaffin cells). Research into L-VGCCs was stimulated by the discovery that the known L-VGCC isoforms (Ca(V)1.1, Ca(V)1.2, Ca(V)1.3 and Ca(V)1.4) possess different biophysical properties. However, no L-VGCC-isoform-selective drugs have yet been identified. In this review, we examine Ca(V)1.2 and Ca(V)1.3 isoforms at the level of genetic structure, splice variants, post-translational modifications and functional protein coupling. We discuss candidate Ca(V)1.2- and Ca(V)1.3-specific characteristics as future therapeutic targets in individual organs.
在电压门控钙通道(VGCCs)家族中,L 型钙通道(L-VGCCs)是钙通道阻滞剂的一个既定的治疗靶点,钙通道阻滞剂被广泛用于治疗高血压和心肌缺血。心血管系统以外的 L-VGCCs 还控制着关键的生理过程,如神经元可塑性、感觉细胞功能(如内耳和视网膜)和内分泌功能(如胰岛β细胞和肾上腺嗜铬细胞)。已知的 L-VGCC 同工型(Ca(V)1.1、Ca(V)1.2、Ca(V)1.3 和 Ca(V)1.4)具有不同的生物物理特性,这一发现刺激了对 L-VGCC 的研究。然而,尚未发现 L-VGCC-同工型选择性药物。在这篇综述中,我们在基因结构、剪接变体、翻译后修饰和功能蛋白偶联水平上检查了 Ca(V)1.2 和 Ca(V)1.3 同工型。我们讨论了候选的 Ca(V)1.2 和 Ca(V)1.3 特异性特征,作为各个器官未来的治疗靶点。